HO CHI MINH CITY, April 15, 2024, Pfizer (Vietnam) Limited Company, Vietnam Vaccine Joint Stock Company (VNVC), and Tam Anh General Hospital Ho Chi Minh Joint Stock Company – Tam Anh Research Institute (TAMRI) signed a memorandum of understanding (MoU) to partner on enhancing Healthcare solution in Vietnam.
Photo: Pfizer Vietnam, VNVC, Tam Anh gathered for the signing ceremony
This partnership comes at a critical time, as the healthcare landscape in Vietnam is rapidly evolving. With a growing population and increasing demand for high-quality healthcare, there is a pressing need for innovative solutions to address the challenges facing the healthcare system in Vietnam. One of the key ways in which this partnership aims to address these challenges is through the application of new innovative solutions in healthcare. By leveraging these cutting-edge technologies and approaches, Pfizer Vietnam, VNVC, and Tam Anh hope to enhance healthcare professional decision-making, improve patient education and awareness, and ultimately improve patient outcomes.
The partnership will focus on three key objectives:
This partnership represents a significant step forward in the ongoing efforts to improve healthcare in Vietnam. By combining the expertise and resources of Pfizer Vietnam, VNVC, and Tam Anh, this partnership is poised to make a meaningful impact on the lives of patients in Vietnam.
As a comprehensive strategic partner of Pfizer in the field of vaccination, Ms. Vu Thi Thu Ha, Supply Director of VNVC said: "VNVC is not only the top quality prestigious immunization system in Vietnam, with a network of 170 vaccination centers across more than 50 provinces and cities across the country, a team of nearly 10,000 highly skilled doctors and nurses, but also the only vaccination unit in Vietnam that owns a modern cold storage system. VNVC has the cold chain of international standards with 04 deep total cold storage and more than 170 cold storages located at each vaccination center across the country that can store 400 million vaccine doses at the same time. VNVC also aims to become a pioneer in bringing new and high-quality vaccines to Vietnamese people. Therefore, participating in research and investment in science to work with vaccine manufacturers towards developing new vaccines is a vital mission that VNVC is willing to cooperate with large and prestigious corporations such as Pfizer. For many consecutive years, VNVC has been honored as the No. 1 prestigious pharmaceutical company in Vietnam, affirming the prestige and trust of tens of millions of customers. VNVC will continue to improve the quality of expertise, services, and efforts to become the pioneer immunization system to bring new vaccines to the Vietnamese people."
Sharing about the signing cooperation, Prof. Nguyen Van Tuan, Director of Tam Anh Research Institute, currently Director of the Center for Health Technology, UTS Australia, Academician of the Australian Academy of Medicine (FAHMS), said that Pfizer is a leading pharmaceutical corporation in the world with the strong experience in clinical research. The partnership opens up opportunities to exchange and learn experiences from Pfizer's global clinical trial programs. In addition, TAMRI has a team of clinical experts with strengths in data science and general science. Thus, it can support Pfizer in data analysis and gene analysis... Besides Pfizer, TAMRI has been working with dozens of the world's leading pharmaceutical companies and vaccine companies, such as AstraZeneca (UK), MSD (USA), and currently has at least 10 clinical trials underway.
According to Prof. Nguyen Van Tuan, the cooperation will carry out research on epidemiology, especially diseases caused by pneumococcus and respiratory syncytial virus RSV, clinical trial research programs related to drugs (cardiovascular, respiratory...), and vaccines with Pfizer. In particular, pneumococcus is the leading cause of pneumonia, meningitis, and sepsis... causing hundreds of thousands of deaths of children and adults around the world, especially for children under 05 years old. The respiratory syncytial virus is one of the leading causes of common respiratory diseases in children, such as rhinotracheitis, pneumonia, bronchitis... and increased hospitalization and death rates among older people with underlying medical conditions. However, in Vietnam, studies on pneumococcus and RSV as well as related data are limited.
Anil Argilla, Pfizer President EM Asia Cluster, said, "I am thrilled to announce this partnership between Pfizer Vietnam and VNVC. This collaboration aligns with Pfizer's commitment to improving healthcare and advancing medicine through the use of innovative technologies and data-driven research. By working together, we can make a real difference in the lives of patients in Vietnam and help to achieve our goal of building healthier communities around the world."
Darrell Oh, Pfizer Vietnam General Director, said, "This partnership is a testament to our commitment to improving healthcare in Vietnam. We have worked collaboratively with VNVC over many years with aligned goals to improve patient outcomes through healthcare professionals and patient educational and the utilization of vaccines for preventive care. By combining our expertise and resources, we are confident that we can make a positive impact on healthcare in Vietnam and improve the lives of patients."
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Disclosure Notice
The information contained in this release is as of April 15, 2024. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Media Contact
Minh Ha Ho
+84 987 530 219
[email protected]